Ricci S. Whitlow net worth and biography

Ricci Whitlow Biography and Net Worth

COO of MiMedx Group

Ms. Whitlow joined MIMEDX in January 2023 as Chief Operating Officer. With a demonstrated background in operational leadership, Ms. Whitlow brings to her role more than 30 years of Life Sciences and Pharmaceutical experience.

She has held a variety of senior executive roles, most recently as President, Clinical Supply Services at Catalent Pharma Solutions. Prior to her role at Catalent, Ms. Whitlow’s extensive career has included leadership positions at a number of MedTech and Pharmaceutical companies, including Optinose, LifeCell, Kinetic Concepts, and Johnson & Johnson.

Ms. Whitlow holds a B.S. in Industrial Engineering from Texas A&M University and an MBA from the NYU/LSE/HEC TRIUM program.

What is Ricci S. Whitlow's net worth?: The estimated net worth of Ricci S. Whitlow is at least $2.86 million as of February 16th, 2024. Mr. Whitlow owns 416,321 shares of MiMedx Group stock worth more than $2,855,962 as of December 5th. This net worth approximation does not reflect any other assets that Mr. Whitlow may own. Learn More about Ricci S. Whitlow's net worth.
How do I contact Ricci S. Whitlow?: The corporate mailing address for Mr. Whitlow and other MiMedx Group executives is 1775 W OAK COMMONS COURT NE, MARIETTA GA, 30062. MiMedx Group can also be reached via phone at (770) 651-9100 and via email at [email protected]. Learn More on Ricci S. Whitlow's contact information.
Has Ricci S. Whitlow been buying or selling shares of MiMedx Group?: Ricci S. Whitlow has not been actively trading shares of MiMedx Group within the last three months. Most recently, Ricci S. Whitlow sold 15,271 shares of the business's stock in a transaction on Tuesday, February 20th. The shares were sold at an average price of $8.01, for a transaction totalling $122,320.71. Following the completion of the sale, the chief operating officer now directly owns 401,050 shares of the company's stock, valued at $3,212,410.50. Learn More on Ricci S. Whitlow's trading history.
Who are MiMedx Group's active insiders?: MiMedx Group's insider roster includes Joseph Capper (CEO), William Hulse, IV (General Counsel and Chief Administrative and Compliance Officer), Kimberly Maersk-Moller (Chief Commercial Officer), Doug Rice (CFO), and Ricci Whitlow (COO). Learn More on MiMedx Group's active insiders.
Are insiders buying or selling shares of MiMedx Group?: In the last twelve months, MiMedx Group insiders bought shares 1 times. They purchased a total of 200,000 shares worth more than $1,268,000.00. In the last twelve months, insiders at the sold shares 6 times. They sold a total of 202,318 shares worth more than $1,562,898.34. The most recent insider tranaction occured on November, 6th when insider Kimberly Maersk-Moller sold 58,300 shares worth more than $432,586.00. Insiders at MiMedx Group own 1.7% of the company. Learn More about insider trades at MiMedx Group.
Information on this page was last updated on 11/6/2025.

Ricci S. Whitlow Insider Trading History at MiMedx Group

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
2/20/2024	Sell	15,271	$8.01	$122,320.71	401,050
2/16/2024	Sell	15,493	$8.07	$125,028.51	416,321

Ricci S. Whitlow Buying and Selling Activity at MiMedx Group

MiMedx Group Company Overview

MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a barrier membrane allograft used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; and EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications. The company's products have applications in the areas of wound care, burn, surgical sectors of healthcare. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. was founded in 2006 and is headquartered in Marietta, Georgia.

Today's Range

Now: $6.86

$6.78

$6.95

50 Day Range

MA: $7.00

$6.48

$7.96

2 Week Range

Now: $6.86

$5.79

$10.14

Volume

669,315 shs

Average Volume

768,000 shs

Market Capitalization

$1.02 billion

P/E Ratio

25.41

Dividend Yield

N/A

Beta

1.64